Pressure Mounts For Roche On PD-L1 Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche spent much of its first quarter conference call answering questions about its PD-L1 antibody strategy, particularly if the drug might be ready for regulatory filing in 2015, earlier than expected, and how it will compete effectively following on the heels of two competitors.